Teva again raises guidance as branded drugs lift revenue
Revenue in the third quarter was $4.4 billion, while analysts had predicted $4.2 billion and non-GAAP earnings per share was $0.86, well above the analysts’ consensus of $0.72.
We haven't written up this one. Globes English has the full story — the link below goes straight to it.